ARCA's Bucindolol Clinical Trial Plan Gets FDA Green Light; Firm Evaluates Funding Options
May 19, 2010
ARCA's Bucindolol Clinical Trial Plan Gets FDA Green Light; Firm Evaluates Funding Options
The FDA has approved a trial investigating bucindolol in approximately 3,200 chronic heart failure patients who have a genotype associated with response to the beta-blocker and mild vasodilator.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Suggests Two-Gene Combo Predicts Spectrum of Response to ARCA's Beta Blocker Gencaro
October 24, 2012 / Pharmacogenomics Reporter - BG Medicine Partners with Siemens on Automated Version of Galectin-3 Heart Failure Prognostic
January 7, 2011 / ProteoMonitor - FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
July 25, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter